Methylphenidate ( DrugBank: Methylphenidate )


7 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病7
13多発性硬化症/視神経脊髄炎5
34神経線維腫症1
84サルコイドーシス3
113筋ジストロフィー1
179ウィリアムズ症候群1
206脆弱X症候群1

6. パーキンソン病


臨床試験数 : 2,298 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02879136
(ClinicalTrials.gov)
December 201623/6/2016TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's DiseaseTAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease: A Single Center, Randomized Pilot StudyParkinson's Disease, IdiopathicDrug: Methylphenidate;Other: Physical Therapy;Drug: AtomoxetineHubert FernandezNULLRecruiting18 Years90 YearsAll42Early Phase 1United States
2NCT01244269
(ClinicalTrials.gov)
December 201018/11/2010The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease.Two-phase Randomized Controlled Trial of Low and Moderate Dose Methylphenidate for Non-motor and Postural Symptoms in Parkinson's Disease.Parkinson's DiseaseDrug: Methylphenidate;Drug: Placebo 10;Drug: Placebo 20Laval UniversityFonds de la Recherche en Santé du Québec;Quebec Memory and Motor Skills Disorders Research CenterTerminatedN/A75 YearsBoth6Phase 4Canada
3EUCTR2009-012643-42-NL
(EUCTR)
06/01/201030/11/2009Freezing of gait in Parkinson's disease: in search of the underlying mechanism and the application of a new treatment option - Freezing of gait in Parkinson's diseaseFreezing of gait in Parkinson's disease: in search of the underlying mechanism and the application of a new treatment option - Freezing of gait in Parkinson's disease Parkinson's disease, in particular the symptom Freezing of GaitTrade Name: Ritalin
Product Name: Not applicable
Product Code: Not applicable
INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE
Other descriptive name: Ritalin
University Medical Center GroningenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands
4NCT00914095
(ClinicalTrials.gov)
October 20092/6/2009Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II)Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentric TrialParkinson's Disease;Gait Disorders, Neurologic;DementiaDrug: methylphenidate;Drug: placeboUniversity Hospital, LilleNULLCompleted30 Years80 YearsBoth69Phase 4France
5NCT00526630
(ClinicalTrials.gov)
December 20075/9/2007Methylphenidate for the Treatment of Gait Impairment in Parkinson's DiseaseMethylphenidate for the Treatment of Gain Impairment in Parkinson's Disease: a Randomized Double-Blind, Placebo-Controlled, Cross-over StudyParkinson's Disease;Gait ImpairmentDrug: Methylphenidate (MPD);Drug: PlaceboUniversity of CincinnatiMichael J. Fox Foundation for Parkinson's ResearchCompleted35 Years85 YearsAll23Phase 4United States
6NCT00393562
(ClinicalTrials.gov)
March 200626/10/2006Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's DiseaseComparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: modafinil;Drug: methylphenidateDepartment of Veterans AffairsNULLWithdrawn50 Years80 YearsBoth0N/AUnited States
7NCT00359723
(ClinicalTrials.gov)
July 200431/7/2006Methylphenidate and Parkinson's DiseaseSubacute Trial of Methylphenidate in Parkinson's DiseaseParkinson's DiseaseDrug: methylphenidateOregon Health and Science UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Completed21 YearsN/AAll13Phase 2United States

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,342 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03185065
(ClinicalTrials.gov)
October 4, 20179/6/2017Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple SclerosisTreatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple SclerosisFatigue in Multiple SclerosisDrug: Amantadine;Drug: Modafinil;Drug: Methylphenidate;Drug: PlacebosJohns Hopkins UniversityPatient-Centered Outcomes Research InstituteCompleted18 YearsN/AAll141Phase 3United States
2NCT02286557
(ClinicalTrials.gov)
October 201416/10/2014Testing the Effects of Methylphenidate on Multiple SclerosisTesting the Effects of Methylphenidate on Cognitive Fatigue in Multiple Sclerosis: a Double-blind, Placebo-controlled, Randomized Clinical TrialFatigue in Multiple SclerosisDrug: Methelphenidate;Drug: PlaceboKessler FoundationNULLNot yet recruiting18 Years65 YearsBoth36Phase 2NULL
3NCT01896700
(ClinicalTrials.gov)
July 20138/7/2013Methylphenidate to Improve Balance and Walking in MSMethylphenidate to Improve Balance and Walking in MSMultiple SclerosisDrug: Methylphenidate;Drug: PlaceboOregon Health and Science UniversityPortland VA Medical CenterCompleted20 Years65 YearsAll24Phase 2/Phase 3United States
4NCT01879202
(ClinicalTrials.gov)
December 20127/11/2012Methylphenidate as Treatment Option of Fatigue in Multiple SclerosisMethylphenidate Modified-release as Treatment of MS-associated Fatigue. A Single-center Randomized Double-blind Placebo-controlled Study.Multiple Sclerosis;FatigueDrug: Methylphenidate modified release;Drug: MaltodextrinMedical University of ViennaNULLRecruiting18 YearsN/ABoth96Phase 2Austria
5EUCTR2012-003418-15-AT
(EUCTR)
23/10/201209/11/2012Methylphenidate modified release as treatment of MS-associated fatigue.Methylphenidate modified release as treatment option of MS-associated fatigue. A single-center randomized double-blind placebo-controlled trial. Fatigue is a very common symptom in multiple sclerosis. Its management comprises nonpharmacologic approaches like exercise, cooling procedures and energy conservation programs and as second step pharmacologic therapy. Until now, Amantadine, Modafinil or antidepressants have been used off-label among others, with some success. Until now, methylphenidate has been successfully used to treat fatigue in HIVand parkinson´s disease, data on its efficacy in MS are not available.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Ritalin LA 20mg capsules
Product Name: Methylphenidate modified release 20 mg
INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE
Trade Name: Ritalin LA 30mg capsules
Product Name: Methylphenidate modified release 30 mg
INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE
Trade Name: Ritalin LA 40mg capsules
Product Name: Methylphenidate modified release 40 mg
INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE
Medizinische Universität WienNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Austria

34. 神経線維腫症


臨床試験数 : 137 薬物数 : 213 - (DrugBank : 76) / 標的遺伝子数 : 87 - 標的パスウェイ数 : 200
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00169611
(ClinicalTrials.gov)
January 20049/9/2005NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by MethylphenidateComportemental and Neuropsychologic Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate. A Double-blind Randomised Study Methylphenidate Versus PlaceboNeurofibromatosis Type 1Drug: methylphenidateHospices Civils de LyonNULLCompleted7 Years12 YearsBoth80Phase 4France

84. サルコイドーシス


臨床試験数 : 149 薬物数 : 227 - (DrugBank : 81) / 標的遺伝子数 : 82 - 標的パスウェイ数 : 167
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02643732
(ClinicalTrials.gov)
November 201623/12/2015Fatigue in Sarcoidosis - Treatment With MethylphenidateFatigue in Sarcoidosis - A Feasibility Study Investigating the Treatment of Fatigue in Stable Sarcoidosis Patients Using MethylphenidateSarcoidosis;FatigueDrug: Methylphenidate (overencapsulated);Drug: Placebo (Over-encapsulated tablet)University of East AngliaClinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)Recruiting18 YearsN/AAll30N/AUnited Kingdom
2EUCTR2016-000342-60-GB
(EUCTR)
21/06/201606/02/2019Fatigue and Sarcoidosis: Treatment with MethylphenidateFatigue in Sarcoidosis - A feasibility study investigating the treatment of fatigue in stable sarcoidosis patients using methylphenidate - Fatigue in Sarcoidosis: Treatment with Methylphenidate Sarcoidosis-associated fatigue (Patients with stable sarcoidosis and chronic fatigue)
MedDRA version: 20.1;Level: PT;Classification code 10039486;Term: Sarcoidosis;System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Methylphenidate
Product Name: Methylphenidate 10mg tablets
Product Code: NA
INN or Proposed INN: Methylphenidate
Other descriptive name: None
Norfolk and Norwich University HospitalNULLNot Recruiting Female: yes
Male: yes
30 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom
3NCT00361387
(ClinicalTrials.gov)
June 20067/8/2006Use of Focalin for Fatigue in SarcoidosisRandomized, Double-Blind, Placebo-Controlled Study of Dexmethylphenidate Hydrochloride, (d-MPH) in the Treatment of Fatigue in Sarcoidosis Subjects.SarcoidosisDrug: d-methylphenidateUniversity of CincinnatiNULLCompleted18 YearsN/ABoth12Phase 4United States

113. 筋ジストロフィー


臨床試験数 : 622 薬物数 : 485 - (DrugBank : 99) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 168
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01421992
(ClinicalTrials.gov)
June 20081/6/2011Methylphenidate in Myotonic Dystrophy Type 1Phase 2/3 Study of Efficacy and Tolerability of Methylphenidate in the Treatment of Excessive Daytime Sleepiness in Myotonic Dystrophy Type 1Dystrophia Myotonica 1Drug: Methylphenidate;Drug: PlaceboLaval UniversityNULLCompleted18 Years65 YearsBoth28Phase 2/Phase 3Canada

179. ウィリアムズ症候群


臨床試験数 : 5 薬物数 : 14 - (DrugBank : 8) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 33
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00768820
(ClinicalTrials.gov)
May 20017/10/2008The Psychiatric and Cognitive Phenotypes in Velocardiofacial SyndromeThe Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular FactorsVelocardiofacial Syndrome;Williams Syndrome;Fragile X SyndromeDrug: methylphenidate, fluoxetin, risperidoneThe Chaim Sheba Medical CenterNULLRecruitingN/AN/AAll400Phase 4Israel

206. 脆弱X症候群


臨床試験数 : 104 薬物数 : 87 - (DrugBank : 32) / 標的遺伝子数 : 54 - 標的パスウェイ数 : 79
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00768820
(ClinicalTrials.gov)
May 20017/10/2008The Psychiatric and Cognitive Phenotypes in Velocardiofacial SyndromeThe Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular FactorsVelocardiofacial Syndrome;Williams Syndrome;Fragile X SyndromeDrug: methylphenidate, fluoxetin, risperidoneThe Chaim Sheba Medical CenterNULLRecruitingN/AN/AAll400Phase 4Israel